In the Spotlight...

Small-molecule MHC-II inducers promote immune detection and anti-cancer immunity via editing cancer metabolism

Huang et al. demonstrated that pristane and its derivatives NJNU-0069 and NJNU-0069-003 induced MHC-II expression in cancer cells to potentiate antigen presentation and immune detection, which increas...

IFNγ-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy

Beziaud et al. focused on the role of cancer stem cell (CSC) plasticity in immune evasion following ICB. In mouse breast tumor models, T cell-produced IFNγ increased conversion of non-CSCs to CSCs, wh...

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma

Märkl and Benmebarek et al. demonstrated the modularity and controllability of a combination of a CAR T cell with a synthetic agonistic receptor (SAR; the extracellular domain of EGFRvIII linked to co...

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Lorentzen et al. report the long-term follow-up of 30 anti-PD-1 therapy-naive patients with metastatic melanoma (Cohort A) and 10 patients with progressive disease on anti-PD-1 therapy (Cohort B) trea...

Previous Digests

Personalized PDAC vaccines have entered the clinic

May 31, 2023

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death, and while surgery can be curative, the vast majority of patients relapse and succumb to their disease, even when given additional chemotherapy. While PDAC is generally resistant to...

Targeting NRP2-VEGF to overcome immunosuppression and chemotherapy resistance in aggressive cancers

May 24, 2023

Neuropilin-2 (NRP2) is a transmembrane protein that binds ligands such as vascular endothelial growth factor (VEGF). It is expressed in several tumor types, and overexpressed in aggressive, treatment-resistant tumors, such as triple-negative breast cancer (TNBC), metastatic castration-resistant prostate cancer...

CIMT Annual Meeting 2023

May 17, 2023

The ACIR team attended the CIMT Annual Meeting 2023 in Mainz, Germany. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Tumor immune microenvironment and implications for immunotherapyGuoliang CuiRafi...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Samuel (Sandy) Goldman

Samuel (Sandy) Goldman

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Elaine Yee Lin Chung

Elaine Yee Lin Chung

Nathan Suek

Nathan Suek

Margot O'Toole

Margot O'Toole

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.